EPISODE · Feb 4, 2026 · 33 MIN
S4, E2: From Medicine to IPOs - Dr Sheila Gujrathi on Raising Biotech Against the Odds
from Raising Biotech · host Surani Fernando
In this episode, we focus on the personal journey of Sheila Gujrathi, a physician turned biotech builder whose career spans medicine, big pharma, rapid IPOs, and billion dollar exits. We explore what it takes to raise biotech across cycles, from early clinical development to public markets, and how Sheila navigated building companies while operating in environments where she was rarely the default. Surani speaks with Sheila about growing up as the child of Indian immigrant physicians, making unconventional career decisions, and learning to balance patients, capital, and leadership under pressure. They discuss her time at Genentech and Bristol Myers Squibb, her role in scaling Receptos through IPO and a $7.2 billion acquisition, the founding and listing of Gossamer Bio, and how those experiences shaped her perspective on leadership and led to her writing The Mirror Effect. 00:00: Introduction 01:45: Growing up as the child of Indian immigrant physicians and early expectations around medicine 04:50: Loss, identity, and the year in India that helped shape a personal North Star going into Medical School 10:30: Leaving clinical medicine and stepping into consulting and industry 15:45: Joining Receptos, building from the ground up, and the road to IPO and acquisition 22:50: Founding Gossamer Bio, raising private capital, and going public in just over a year 30:10: Reflection, writing The Mirror Effect, and building pathways for the next generation For more on Sheila's Book, click here For any comments, questions or feedback you can connect directly with Surani Fernando on LinkedIn or email: [email protected] Title music composed by: Yrii Semchyshyn (Coma Media)
NOW PLAYING
S4, E2: From Medicine to IPOs - Dr Sheila Gujrathi on Raising Biotech Against the Odds
No transcript for this episode yet
Similar Episodes
May 1, 2026 ·24m
Mar 27, 2026 ·30m
Feb 27, 2026 ·30m
Feb 4, 2026 ·72m
Jan 23, 2026 ·29m
Dec 11, 2025 ·27m